CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice

Open access

Abstract

Pancreatic ductal adenocarcinoma (PDAC), a highly lethal disease with limited therapeutic options, may benefit from repurposing of FDA-approved drugs in preventive or interceptive strategies in high-risk populations. Previous animal studies demonstrated that the use of metformin and statins as single agents at relatively high doses restrained PDAC development. Here, four-week-old mice expressing KrasG12D in all pancreatic lineages (KC mice) and fed an obesogenic high fat, high calorie diet that promotes early PDAC development were randomized onto low dosage metformin, simvastatin, or both drugs in combination administered orally. Dual treatment attenuated weight gain, fibro-inflammation, and development of advanced PDAC precursor lesions (pancreatic intraepithelial neoplasia [PanIN]-3) in male KC mice, without significant effect in females or when administered individually. Dual-treated KC mice had reduced proliferation of PanIN cells and decreased transcriptional activity of the Hippo effectors, YAP and TAZ, which are important regulators of PDAC development. Metformin and simvastatin also synergistically inhibited colony formation of pancreatic cancer cells in vitro. Together, our data demonstrated that a combination of low doses of metformin and simvastatin inhibits PDAC development and imply that both drugs are promising agents for being tested in clinical trials for preventing pancreatic cancer progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-023-43498-9

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Weekly weight gain in male (left panel) and female (right panel) KC mice fed the control diet (CD), high fat, high calorie diet (HFCD), HFCD plus metformin (Met), HFCD plus simvastatin (Sim), or HFCD plus metformin and simvastatin (Met Sim). ***p ≤ 0.001, ns = not significant. (B) Weight gain at the end of the study (after 3 months of treatment) in male (left panel) and female (right panel) KC mice fed the CD, HFCD, HFCD + Met, HFCD + Sim, or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). ***p ≤ 0.001, **p ≤ 0.01, ns = not significant.
Figure 1 (A) Weekly weight gain in male (left panel) and female (right panel) KC mice fed the control diet (CD), high fat, high calorie diet (HFCD), HFCD plus metformin (Met), HFCD plus simvastatin (Sim), or HFCD plus metformin and simvastatin (Met Sim). ***p ≤ 0.001, ns = not significant. (B) Weight gain at the end of the study (after 3 months of treatment) in male (left panel) and female (right panel) KC mice fed the CD, HFCD, HFCD + Met, HFCD + Sim, or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). ***p ≤ 0.001, **p ≤ 0.01, ns = not significant.CC BY · PubMed Central
Figure 2 (A) Representative microscopic images of the pancreas of male KC mice fed the high fat, high calorie diet (HFCD) (left column) or HFCD plus metformin (Met) and simvastatin (Sim) (right column). In the first row, tissue sections were stained with hematoxylin and eosin (scale bar: 400 µm). In the second row, tissue was stained with Sirius red (scale bar: 400 µm). The third row represents QuPath analysis of stromal cells highlighted in green (scale bar: 500 µm). (B) Percentage of intact pancreatic acini, (C) pancreatic inflammation score, and (D) percentage of stromal cells in male (left panel) and female (right panel) KC mice fed the control diet (CD), HFCD, HFCD + Met, HFCD + Sim, or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, ns = not significant.
Figure 2 (A) Representative microscopic images of the pancreas of male KC mice fed the high fat, high calorie diet (HFCD) (left column) or HFCD plus metformin (Met) and simvastatin (Sim) (right column). In the first row, tissue sections were stained with hematoxylin and eosin (scale bar: 400 µm). In the second row, tissue was stained with Sirius red (scale bar: 400 µm). The third row represents QuPath analysis of stromal cells highlighted in green (scale bar: 500 µm). (B) Percentage of intact pancreatic acini, (C) pancreatic inflammation score, and (D) percentage of stromal cells in male (left panel) and female (right panel) KC mice fed the control diet (CD), HFCD, HFCD + Met, HFCD + Sim, or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, ns = not significant.CC BY · PubMed Central
Figure 3 (A) Representative microscopy images of the pancreas stained with hematoxylin and eosin (top row; scale bar: 20 µm) or Alcian blue (bottom row; scale bar: 50 µm) of male KC mice fed the control diet (CD, left panels) or high fat, high calorie diet (HFCD, right panels). (B) Percentage of PanIN-3 lesions in male (left panel) and female (right panel) KC mice fed the CD, HFCD, HFCD + metformin (Met), HFCD + simvastatin (Sim), or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). ***p ≤ 0.001, *p ≤ 0.05, ns = not significant. (C) Percentage of the area of Alcian blue positive lesions in relation to the entire cross section of the pancreas in male KC mice fed the HFCD or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). **p ≤ 0.01. (D) Percentage of the area covered by ADM lesions in relation to the entire cross section of the pancreas in male KC mice fed the HFCD or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). ***p ≤ 0.001. (E) Percentage of low-grade PanIN-1 and -2 lesions in male KC mice fed the HFCD or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). **p ≤ 0.01. (F) Representative microscopy images of the pancreas stained with antibodies against Ki67 (upper row) of male KC mice fed the HFCD (left panel) or HFCD + Met + Sim (right panel) (scale bar: 50 µm). Brown staining indicates positivity for Ki67. Lower row represents QuPath images for automatic quantification of Ki67-positive PanIN cells of the same images shown in the top row. (G) Percentage of Ki67-positive PanIN cells in male (left panel) and female (right panel) KC mice fed the HFCD, HFCD + Met, HFCD + Sim, or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). *p ≤ 0.05, ns = not significant.
Figure 3 (A) Representative microscopy images of the pancreas stained with hematoxylin and eosin (top row; scale bar: 20 µm) or Alcian blue (bottom row; scale bar: 50 µm) of male KC mice fed the control diet (CD, left panels) or high fat, high calorie diet (HFCD, right panels). (B) Percentage of PanIN-3 lesions in male (left panel) and female (right panel) KC mice fed the CD, HFCD, HFCD + metformin (Met), HFCD + simvastatin (Sim), or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). ***p ≤ 0.001, *p ≤ 0.05, ns = not significant. (C) Percentage of the area of Alcian blue positive lesions in relation to the entire cross section of the pancreas in male KC mice fed the HFCD or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). **p ≤ 0.01. (D) Percentage of the area covered by ADM lesions in relation to the entire cross section of the pancreas in male KC mice fed the HFCD or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). ***p ≤ 0.001. (E) Percentage of low-grade PanIN-1 and -2 lesions in male KC mice fed the HFCD or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). **p ≤ 0.01. (F) Representative microscopy images of the pancreas stained with antibodies against Ki67 (upper row) of male KC mice fed the HFCD (left panel) or HFCD + Met + Sim (right panel) (scale bar: 50 µm). Brown staining indicates positivity for Ki67. Lower row represents QuPath images for automatic quantification of Ki67-positive PanIN cells of the same images shown in the top row. (G) Percentage of Ki67-positive PanIN cells in male (left panel) and female (right panel) KC mice fed the HFCD, HFCD + Met, HFCD + Sim, or HFCD + Met + Sim. Data are presented as scatter plots with bars (mean ± SD). *p ≤ 0.05, ns = not significant.CC BY · PubMed Central
Figure 4 (A) Representative microscopy images of the pancreas stained with antibodies against YAP (left column) or TAZ (right column) of male KC mice fed the control diet (CD, top row), high fat, high calorie diet (HFCD, middle row), or HFCD + metformin (Met) + simvastatin (Sim) (bottom row). Brown staining indicates positivity for YAP or TAZ. Black arrowheads point to epithelial (PanIN, ADM) cells, and red arrowheads to stromal cells positive for YAP or TAZ (scale bar: 50 µm for top row and 20 µm for middle and bottom row). Upper inset shows a PanIN cell with nuclear and cytoplasmic YAP staining; lower inset depicts a PanIN cell with strong exclusive nuclear YAP staining. (B) Real-time quantitative PCR analysis of Ctgf (left column), Cyr61 (middle column), and Amotl2 (right column) mRNA expression in the pancreas of male (upper row) and female (lower row) KC mice fed the CD, HFCD, HFCD + Met, HFCD + Sim, or HFCD + Met + Sim. *p ≤ 0.05, ns = not significant.
Figure 4 (A) Representative microscopy images of the pancreas stained with antibodies against YAP (left column) or TAZ (right column) of male KC mice fed the control diet (CD, top row), high fat, high calorie diet (HFCD, middle row), or HFCD + metformin (Met) + simvastatin (Sim) (bottom row). Brown staining indicates positivity for YAP or TAZ. Black arrowheads point to epithelial (PanIN, ADM) cells, and red arrowheads to stromal cells positive for YAP or TAZ (scale bar: 50 µm for top row and 20 µm for middle and bottom row). Upper inset shows a PanIN cell with nuclear and cytoplasmic YAP staining; lower inset depicts a PanIN cell with strong exclusive nuclear YAP staining. (B) Real-time quantitative PCR analysis of Ctgf (left column), Cyr61 (middle column), and Amotl2 (right column) mRNA expression in the pancreas of male (upper row) and female (lower row) KC mice fed the CD, HFCD, HFCD + Met, HFCD + Sim, or HFCD + Met + Sim. *p ≤ 0.05, ns = not significant.CC BY · PubMed Central
Figure 5 Colony formation assay of murine KC (A), PANC-1 (B), and MIA PaCa-2 (C) cells treated with 0.3 µM simvastatin (Sim), 0.05 mM metformin (Met), or a combination of both. Data are presented as scatter plots with bars (mean ± SD). **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, ns = not significant. (D) Synergistic effects of metformin and simvastatin on inhibition of colony formation in PANC-1 cells were analyzed by isobologram analysis. The EC50 of simvastatin and metformin were 0.45 µM and 0.25 mM, respectively. Red circles represent the EC50 of metformin with simvastatin at 0.1 or 0.25 µM; their position under the isobole indicates a synergistic effect. Inset: Dose response of metformin (Met) without or with simvastatin (Sim).
Figure 5 Colony formation assay of murine KC (A), PANC-1 (B), and MIA PaCa-2 (C) cells treated with 0.3 µM simvastatin (Sim), 0.05 mM metformin (Met), or a combination of both. Data are presented as scatter plots with bars (mean ± SD). **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, ns = not significant. (D) Synergistic effects of metformin and simvastatin on inhibition of colony formation in PANC-1 cells were analyzed by isobologram analysis. The EC50 of simvastatin and metformin were 0.45 µM and 0.25 mM, respectively. Red circles represent the EC50 of metformin with simvastatin at 0.1 or 0.25 µM; their position under the isobole indicates a synergistic effect. Inset: Dose response of metformin (Met) without or with simvastatin (Sim).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 13

Metadata

Authors
Teper, Y., Ye, L., Waldron, R. T., Lugea, A., Sun, X., Sinnett-Smith, J., Hines, O. J., Pandol, S. J., Rozengurt, E., & Eibl, G.
Affiliations
  • University of California, Los Angeles (US)
  • Cedars-Sinai Medical Center (US)
Corresponding author
Eibl, Guido
Venue
Scientific Reports
Published
2023-09-26
Volume
13
Issue
1
Pages
16144-16144
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4387038650
Cited by
10
References
49
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2023: 1
FWCI
1.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Veterans Affairs (I01 BX003801)
  • Hirshberg Foundation for Pancreatic Cancer Research
  • National Institutes of Health
  • National Cancer Institute (R21CA258125, P01CA236585)
  • National Institute of Allergy and Infectious Diseases (R21AI156592)
  • National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007180)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
metformin, simvastatin, combination therapy, pancreatic ductal adenocarcinoma, obesity, pancreatic intraepithelial neoplasia, Hippo signaling pathway, YAP, TAZ, drug repurposing, cancer prevention, high-fat high-calorie diet, synergistic antiproliferative effect
MeSH terms
Animals, Female, Male, Obesity, Pancreatic Neoplasms, Simvastatin, Carcinoma, Pancreatic Ductal, Mice, Adenocarcinoma in Situ

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. https://app.cochat.ai/papers/10.1038/s41598-023-43498-9
The paper
Teper, Y., Ye, L., Waldron, R. T., Lugea, A., Sun, X., Sinnett-Smith, J., Hines, O. J., Pandol, S. J., Rozengurt, E., & Eibl, G. (2023). Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. Scientific Reports. https://doi.org/10.1038/s41598-023-43498-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.